Zoetis Inc. (NYSE:ZTS) Stake Lifted by Capital International Inc. CA

Capital International Inc. CA raised its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 11.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 70,573 shares of the company's stock after purchasing an additional 7,457 shares during the period. Capital International Inc. CA's holdings in Zoetis were worth $11,498,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Atlantic Edge Private Wealth Management LLC lifted its stake in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after buying an additional 140 shares in the last quarter. Rakuten Securities Inc. raised its position in Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 166 shares during the period. Murphy & Mullick Capital Management Corp acquired a new stake in shares of Zoetis during the fourth quarter worth about $44,000. Asset Planning Inc acquired a new stake in shares of Zoetis in the fourth quarter valued at $58,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new stake in Zoetis in the fourth quarter valued at approximately $59,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on ZTS. Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Stifel Nicolaus dropped their target price on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Piper Sandler increased their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Thursday, February 27th. Finally, Barclays raised their target price on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $214.40.

Insider Activity at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares of the company's stock, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 1,862 shares of company stock worth $312,254. Corporate insiders own 0.16% of the company's stock.

Zoetis Trading Up 1.1 %

ZTS stock traded up $1.61 during midday trading on Thursday, hitting $152.52. The stock had a trading volume of 2,147,318 shares, compared to its average volume of 2,520,868. The firm has a market cap of $68.05 billion, a PE ratio of 27.88, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The company's 50-day moving average price is $159.06 and its 200 day moving average price is $169.10.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.31%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's payout ratio is currently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.